Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Enoblituzumab in Localized Prostate Cancer
NCT02923180Phase 2Active, not recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Feb 2017
- Primary completion
- Aug 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enoblituzumab in prostate cancer (PCa), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Number of Participants With Treatment-related Adverse Events at 2 years and Efficacy of Neoadjuvant Enoblituzumab as Assessed by PSA0 Response Rate at 12 months. Started Feb 2017; status: active, not recruiting.
02
Drugs
enoblituzumab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02923180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02923180.